Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

This study has been completed.
Sponsor:
Information provided by:
Laboratoires Thea
ClinicalTrials.gov Identifier:
NCT01155999
First received: June 30, 2010
Last updated: September 9, 2011
Last verified: September 2011
  Purpose

Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.


Condition Intervention Phase
Purulent Bacterial Conjunctivitis
Drug: T1225
Drug: Tobramycin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Laboratoires Thea:

Primary Outcome Measures:
  • Clinical cure [ Time Frame: Day 3 ] [ Designated as safety issue: Yes ]
    • a score 0 for bulbar conjunctival injection
    • a score 0 for conjunctival discharge


Secondary Outcome Measures:
  • Clinical efficacy criteria [ Time Frame: Day 3 and day 7 ] [ Designated as safety issue: Yes ]
    • Day 3:

      • clinical improvement for the worse eye
      • clinical status

        • for the "other eye"
        • for "both eyes"
    • Day 7:

      • clinical status for the "worse eye"
      • clinical status for the "other eye"
      • clinical status for "both eyes"

  • Bacteriological efficacy [ Time Frame: Day 0 and Day 7 ] [ Designated as safety issue: Yes ]
    Bacterial outcome


Estimated Enrollment: 222
Study Start Date: December 2008
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: T1225 Drug: T1225
one drop twice daily (morning and evening) in each eye from Day 0 to Day 2
Active Comparator: Tobramycin Drug: Tobramycin
1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6

  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ one day of life and ≤ 18 years
  • Purulent bacterial conjunctivitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01155999

Locations
France
Clermont-Ferrand, France, 63000
Sponsors and Collaborators
Laboratoires Thea
  More Information

No publications provided

Responsible Party: Medical Director, Laboratoires Théa
ClinicalTrials.gov Identifier: NCT01155999     History of Changes
Other Study ID Numbers: LT1225-PIIIB-02/08, 2008-003567-39
Study First Received: June 30, 2010
Last Updated: September 9, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Belgium: Federal Agency for Medicinal Products and Health Products
Portugal: National Pharmacy and Medicines Institute
Spain: Spanish Agency of Medicines
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Romania: National Medicines Agency
Tunisia: Ministry of Public Health
Algeria: Ministry of Health
Italy: The Italian Medicines Agency

Additional relevant MeSH terms:
Conjunctivitis
Conjunctivitis, Bacterial
Conjunctival Diseases
Eye Diseases
Eye Infections, Bacterial
Bacterial Infections
Eye Infections
Infection
Tobramycin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 20, 2014